| Identification | Back Directory | [Name]
FOSALVUDINE TIDOXIL | [CAS]
763903-67-9 | [Synonyms]
HDP990003 HDP-990003 HDP 990003 HDP99.0003 HDP-99.0003 HDP 99.0003 FOSALVUDINE TIDOXIL JHXLLEDIXXOJQD-WELGVCPWSA-N 5'-Thymidylic acid, 3'-deoxy-3'-fluoro-, mono[2-(decyloxy)-3-(dodecylthio)propyl] ester | [Molecular Formula]
C35H64FN2O8PS | [MDL Number]
MFCD09954123 | [MOL File]
763903-67-9.mol | [Molecular Weight]
722.93 |
| Hazard Information | Back Directory | [Uses]
Fosalvudine tidoxil is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Fosalvudine tidoxil is a prodrug derived from Alovudine (HY-B1516). Fosalvudine tidoxil is less toxic than Alovudine and can be used for the research of HIV-1 infection[1]. | [in vivo]
Fosalvudine tidoxil (15-100 mg/kg/day; oral; 8 weeks) induces significant mitochondrial hepatotoxicity in rats[1]. | Animal Model: | Sprague-Dawley rats[1] | | Dosage: | 15, 40, or 100 mg/kg/day | | Administration: | Oral gavage, 8 weeks | | Result: | Induced significant mtDNA depletion. At doses of 15, 40, and 100 mg/kg, the mean hepatic mtDNA values were 62, 64, and 47% of control values, respectively. |
| [References]
[1] Venhoff AC, et al. Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug. Antimicrob Agents Chemother. 2009 Jul;53(7):2748-51. DOI:10.1128/AAC.00364-09 |
|
|